CTOs on the Move

Siolta Therapeutics

www.sioltatherapeutics.com

 
Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Siolta Therapeutics raised $30M on 09/22/2020

Similar Companies

Obsidian Therapeutics

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian`s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we`re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge, we`re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.

Neurogene

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.

EcoArray

EcoArray is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GPB Scientific

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.